Obesity Modulates the Immune Response to Oxidized LDL in Hypertensive Patients

Cell Biochemistry and Biophysics

Volumn 67, Issue 3, 2013, Pages 1451-1460

  Fonseca, Henrique Andrade R ^a   Fonseca, Francisco A ^a,c   Monteiro, Andrea M ^b,c   Bianco, Henrique T ^a   Boschcov, Paulo ^a   Brandão, Sergio A ^a   Juliano, Luiz ^a   Gidlund, Magnus ^b,d   Izar, Maria C ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c National Institute of Complex Fluids   (Brazil)

^d National Institute of Nanomaterials for Integrated Markers   (Brazil)

Author keywords

Autoantibodies; Body mass index; Hypertension; Inflammation; Oxidized LDL

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN D; AUTOANTIBODY; INTERLEUKIN 10; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; FEMALE; HUMAN; HYPERTENSION; IMMUNOLOGY; LIPID PEROXIDATION; MALE; METABOLISM; MIDDLE AGED; OBESITY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS B; APOLIPOPROTEINS D; AUTOANTIBODIES; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-10; INTERLEUKIN-8; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MONITORING, AMBULATORY; OBESITY;

EID: 84888316420     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9585-9     Document Type: Article

References (42)

1. World Health Organization Report. Burden: Mortality, morbidity, and risk factors in 2008. www. who. int/nmh/publications/ncd_report.
2. Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., et al. (2007). Explaining the decrease in the U. S. deaths from coronary disease, 1908-2000. New England Journal of Medicine, 356, 2388-2398.
3. Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444, 860-867.
4. Després, J. P., & Lemieux, I. (2006). Abdominal obesity and metabolic syndrome. Nature, 444, 881-887.
5. Harrison, D. G., Guzik, T. J., Lob, H. E., Madhur, M. S., Marvar, P. J., Thabet, S. R., et al. (2011). Inflammation, immunity, and hypertension. Hypertension, 57, 132-140.
6. Sima, A. V., Stancu, C. S., & Simionescu, M. (2009). Vascular endothelium in atherosclerosis. Cell Tissue Research, 335, 191-203.
7. Tabas, I., Willians, K. J., & Boren, J. (2007). Subendothelial lipoprotein retention as the initiation process in atherosclerosis: Update and therapeutics implications. Circulation, 116, 1832-1844.
8. Esterbauer, H., Gebicki, J., Puhl, H., & Jürgens, G. (1992). The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology & Medicine, 13, 341-390.
9. Steinberg, D. (2009). The LDL modification hypothesis of atherogenesis: An update. Journal of Lipid Research, 50(Suppl), S376-S381.
10. Libby, P., Ridker, P. M., & Hansson, G. K. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature, 473, 317-325.
11. Ketelhuth, D. F., Rios, F. J., Wang, Y., Liu, H., Johansson, M. E., Fredrikson, G. N., et al. (2011). Identification of a danger-associated peptide from apolipoproteinB100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation, 124, 2433-2443.
12. Svensjo, E., Boschcov, P., Ketelhuth, D. F., Jancar, S., & Gidlund, M. (2003). Increased microvascular permeability in the hamster cheek pouch induced by oxidized low-density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflammation Research, 52, 215-220.
13. Chyu, K. Y., Zhao, X., Dimayuga, P. C., Zhou, J., Li, X., Yano, J., et al. (2012). CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. PLoS ONE, 7, e30780.
14. Stocker, R., & Keaney, J. F, Jr. (2004). Role of oxidative modifications in atherosclerosis. Physiological Review, 84, 1381-1478.
15. da Fonseca, H. A., Fonseca, F. A., Monteiro, A. M., Farias, N. C, Jr, Bianco, H. T., Brandão, S. A., et al. (2012). Inflammatory environment and immune responses to oxidized LDL are linked to systolic and diastolic blood pressure levels in hypertensive subjects. International Journal of Cardiology, 157, 131-133.
16. Soares, S. R., Carvalho-Oliveira, R., Ramos-Sanchez, E., Catanozi, S., da Silva, L. F., Mauad, T., et al. (2009). Air pollution and antibodies against modified lipoproteins are associated with atherosclerosis and vascular remodeling in hyperlipemic mice. Atherosclerosis, 207, 368-373.
17. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L, Jr, et al. (2003). National Heart, Lung, and Blood Institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; National High Blood Pressure Education Program Coordinating Committee: the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 289, 2560-2571.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII), (2001) JAMA, 285, 2486-2497.
19. Emerging Risk Factors Collaboration, Wormser, D., Kaptoge, S., Di Angelantonio, E., Wood, A. M., Pennells, L., et al. (2011). Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet, 377, 1085-1095.
20. Bogers, R. P., Bemelmans, W. J., Hoogenveen, R. T., Boshuizen, H. C., Woodward, M., Knekt, P., et al. (2007). Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: A meta-analysis of 21 cohort studies including more than 300 000 persons. Archives of Internal Medicine, 167, 1720-1728.
21. Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
22. Cockcroft, D. W., & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
23. Puhl, H., Waeg, G., & Esterbauer, H. (1994). Methods to determine oxidation of low-density lipoproteins. Methods in Enzymology, 233, 425-441.
24. Fernvik, E. C., Ketelhuth, D. J., Russo, M., & Gidlund, M. (2004). The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients. Journal of Clinical Immunology, 24, 170-176.
25. Brandão, S. A., Izar, M. C., Fischer, S. M., Santos, A. O., Monteiro, C. M., Póvoa, R. M., et al. (2009). Early increase in autoantibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control. American Journal of Hypertension, 23, 208-214.
26. Schillaci, G., Verdecchia, P., Borgioni, C., Ciucci, A., Guerrieri, M., Zampi, I., et al. (1994). Improved electrocardiographic diagnosis of left ventricular hypertrophy. American Journal of Cardiology, 74, 714-719.
27. Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., Creager, M. A., et al. (2002). International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal American College of Cardiology, 39, 257-265.
28. Wu, R., de Faire, U., Lemne, C., Witztum, J. L., & Frostegård, J. (1999). Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension, 33, 53-59.
29. Frostegård, J., Wu, R., Lemne, C., Thulin, T., Witztum, J. L., & de Faire, U. (2003). Circulating oxidized low-density lipoprotein is increased in hypertension. Clinical Science, 105, 615-620.
30. Izar, M. C., Fonseca, H. A., Pinheiro, L. F., Monteiro, C. M., Povoa, R. M., Monteiro, A. M., et al. (2012) Adaptive immunity is related to coronary artery disease severity after acute coronary syndrome in subjects with metabolic syndrome. Diabetes Vascular Disease and Research, epub.
31. Santos, A. O., Fonseca, F. A., Fischer, S. M., Monteiro, C. M., Brandão, S. A., Póvoa, R. M., et al. (2009). High circulating autoantibodies against oxidized Low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clinica Chimica Acta, 406, 113-118.
32. Shoji, T., Nishizawa, Y., Fukumoto, M., Shimamura, K., Kimura, J., Kanda, H., et al. (2000). Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis, 148, 171-177.
33. Sjögren, P., Fredrikson, G. N., Samnegard, A., Ericsson, C. G., Ohrvik, J., Fisher, R. M., et al. (2008). High plasma concentration of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. European Heart Journal, 29, 2218-2226.
34. Tsimikas, S., Brilakis, E. S., Lennon, R. J., Miller, E. R., Witztum, J. L., McConnell, J. P., et al. (2007). Relationship of IgG and IgM autoantibodies to oxidized low-density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research, 48, 425-433.
35. Tsimikas, S., Bergmark, C., Beyer, R. W., Patel, R., Pattison, J., Miller, E., et al. (2003). Temporal increase in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. Journal of American College of Cardiology, 41, 360-370.
36. Ait-Oufella, H., Herbin, O., Bouaziz, J. D., Binder, C. J., Uyttenhove, C., Laurans, L., et al. (2010). B-cell depletion reduces the development of atherosclerosis in mice. Journal of Experimental Medicine, 207, 1579-1587.
37. Ameli, S., Hultgårdh-Nilsson, A., Regnström, J., Calara, F., Yano, J., Cercek, B., et al. (1996). Effects of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 1074-1079.
38. Hansson, G. K., & Hermansson, A. (2011). The immune system in atherosclerosis. Nature Immunology, 12, 204-212.
39. Fredrikson, G. N., Anand, D. V., Hopkins, D., Corder, R., Alm, R., Bengtsson, E., et al. (2009). Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia, 52, 1426-1433.
40. Klingenberg, R., Lebens, M., Hermansson, A., Fredrikson, G. N., Strodthoff, D., Rudling, M., et al. (2010). Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 946-952.
41. Fichtlscherer, S., Breuer, S., Heeschen, C., Dimmeler, S., & Zeiher, A. M. (2004). Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. Journal of American College of Cardiology, 44, 44-49.
42. Kim, C. S., Park, H. S., Kawada, T., Kim, J. H., Lim, D., Hubbard, N. E., et al. (2006). Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. International Journal of Obesity. (Lond), 30, 1347-1355.